Loading organizations...
§ Private Profile · San Francisco, CA, USA
AI-powered innovation platform for health and life sciences companies, focused on bioactive discovery and ingredient development.
Brightseed is a South San Francisco, California-based health and life sciences company that provides an artificial intelligence-driven platform to discover, validate, and commercialize bioactive compounds. The company utilizes its proprietary AI tool, Forager, to analyze a dataset of over 11 million bioactives across 23 distinct health areas, accelerating the biological discovery process from years to months. Operating primarily on a platform-first subscription model, the organization serves clients across the food and beverage, specialized nutrition, and consumer health sectors. Brightseed is backed by over 40 industry partners and has established strategic collaborations with recognizable organizations such as Haleon and the Almond Board of California. Recent joint research efforts have successfully identified 530 phytochemicals in almonds, including six compounds reported for the first time. The company was founded in 2017 by Lee Chae and Sofia Elizondo.
Brightseed has raised $123.6M across 4 funding rounds.
Brightseed has raised $123.6M in total across 4 funding rounds.
Brightseed has raised $123.6M in total across 4 funding rounds.
Brightseed's investors include Bill & Melinda Gates Foundation, Temasek, Gabriel Ruimy, Brkfst Club, Main Sequence Ventures, Mayfield, McWin Capital Partners, NEO, SOSV, UpHonest Capital, Vamos Ventures, Gary Hirshberg.
Brightseed has raised $123.6M across 4 funding rounds. Most recently, it raised $1.6M Grant in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 19, 2023 | $1.6M Grant | Bill & Melinda Gates Foundation | — | Announced |
| May 1, 2022 | $68M Series B | Temasek | Gabriel Ruimy, Brkfst Club, Main Sequence Ventures, Mayfield, Mcwin Capital Partners, NEO, SOSV, UpHonest Capital, Vamos Ventures, Gary Hirshberg, Hadi Partovi, Scott Banister, AgFunder, Continental Grain Company, Germin8 Ventures, Lewis & Clark Agrifood, S2G Ventures | Announced |
| Sep 15, 2020 | $27M Venture Round | — | AgFunder, Continental Grain Company, Fifty Years, Germin8 Ventures, Horizons Ventures, David Russell, S2G | Announced |
| Sep 1, 2020 | $27M Series U | — | Brick & Mortar Ventures, S3 Ventures, AgFunder, Continental Grain Company, Fifty Years, Germin8 Ventures, Horizons Ventures, Lewis & Clark Agrifood, S2G | Announced |
Brightseed is a biotechnology company founded in 2017 and headquartered in San Francisco, California, that develops AI-powered technology to discover hidden bioactive compounds in plants for applications in human health, nutrition, and wellness.[1][2] It serves industries like food, supplements, and pharmaceuticals by unlocking plant-based ingredients that address health challenges, such as enabling healthier futures through novel compounds revealed by its AI platform.[1][2][3] The company has raised $120.8 million in funding, employs 10-100 people, and shows growth momentum through partnerships with investors like Temasek and a leadership team driving commercialization of AI-discovered bioactives.[1][2]
Brightseed was co-founded in 2017 by Lee Chae (CTO), Sofia Elizondo (COO), Philip Dickinson, and Jim Flatt (CEO), who brought expertise in technology, operations, and biotech to pioneer AI-driven discovery of plant compounds.[1][2] The idea emerged from recognizing nature's untapped potential, using computational biology and machine learning to illuminate connections between plants and human health—addressing the limitations of traditional screening methods.[1][3] Early traction came from securing significant venture funding and building a team under CEO Jim Flatt, positioning it as a leader in AI-biotech innovation without acquisition or IPO to date.[1][2]
Brightseed stands out in biotech through these key strengths:
Brightseed rides the AI-biotech convergence trend, where machine learning decodes nature's complexity to fuel precision nutrition and personalized health amid rising demand for plant-based alternatives to synthetic drugs.[1][2][3] Timing is ideal as global focus on sustainability, chronic disease prevention, and clean-label ingredients intensifies post-pandemic, with market forces like regulatory support for natural bioactives and investor interest in healthtech (e.g., comparables like Virta Health or Ro) propelling growth.[2] It influences the ecosystem by democratizing access to plant intelligence, partnering with food/pharma giants to shift industries toward AI-accelerated, nature-positive innovation.
Brightseed is poised for expansion by scaling AI-discovered compounds into commercial products, potentially through more partnerships or pre-IPO liquidity events via platforms tracking its valuation.[2] Trends like AI advancements in biology, rising plant-based demand, and sustainability mandates will shape its path, evolving its influence from discovery pioneer to key supplier in a $100B+ functional ingredients market. As biotech matures, expect Brightseed to deepen ecosystem impact, illuminating nature's role in healthier futures—just as its technology reveals hidden compounds in plants.